Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Elutia Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 22 | 26 | +4 |
| Shares | 5.69M | 8.97M | +3.28M (+57.7%) |
| Value | $17.9M | $44.5M | +$26.6M (+148.3%) |
New holders (5)
Institutions that held Elutia Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kennedy Capital Management, Inc. | 200,000 | $992.0K | 0.02% |
| Alyeska Investment Group, L.P. | 91,977 | $456.2K | 0.00% |
| EAM Investors, LLC | 25,260 | $125.3K | 0.02% |
| Jane Street Group, LLC | 10,497 | $52.1K | 0.00% |
| Arcus Capital Partners, LLC | 10,000 | $49.6K | 0.02% |
Sold out (1)
Institutions that held Elutia Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Wells Fargo & Company | 112 | $353 |